Drug Patents owned by Mycovia Pharms

1. Drug name - VIVJOA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8236962 MYCOVIA PHARMS Metalloenzyme inhibitor compounds
Apr, 2031

(8 years from now)

US10414751 MYCOVIA PHARMS Antifungal compounds and processes for making
Mar, 2036

(13 years from now)

US9840492 MYCOVIA PHARMS Antifungal compounds and processes for making
Mar, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8754227 MYCOVIA PHARMS Metalloenzyme inhibitor compounds
Apr, 2031

(8 years from now)

US11247981 MYCOVIA PHARMS Metalloenzyme inhibitor compounds
May, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 26, 2027
Generating Antibiotic Incentives Now (GAIN) Apr 26, 2032

Drugs and Companies using OTESECONAZOLE ingredient

Market Authorisation Date: 26 April, 2022

Treatment: Vivjoa is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (rvvc) in females with a history of rvvc who are not of reproductive potential

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
150MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in